FREQUENCY OF APPROPRIATE ACTIVATIONS OF IMPLANTED CARDIOVERTERS-DEFIBRILLATORS IN PATIENTS WITH CHRONIC HEART FAILURE
Abstract
To study frequency of appropriate activations of implanted cardioverters-defibrillators for primary and secondary prevention of sudden cardiac death in patients with chronic heart failure in real clinical practice, 199 patients aged 56±11 years were examined.
About the Authors
A. Yu. Rychkov
Филиал НИИ кардиологии «Тюменский кардиологический центр»
Russian Federation
Russian Federation
V. A. Kuznetsov
Филиал НИИ кардиологии «Тюменский кардиологический центр»
Russian Federation
Russian Federation
E. L. Dyuryagina
Филиал НИИ кардиологии «Тюменский кардиологический центр»
Russian Federation
Russian Federation
N. Yu. Khorkova
Филиал НИИ кардиологии «Тюменский кардиологический центр»
Russian Federation
Russian Federation
E. N. Dubrovskaya
Филиал НИИ кардиологии «Тюменский кардиологический центр»
Russian Federation
Russian Federation
V. E. Kharats
Филиал НИИ кардиологии «Тюменский кардиологический центр»
Russian Federation
Russian Federation
References
1. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) // Lancet. 1999; 353(9169):2001-2007.
2. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр) // Сердечная недостаточность. 2013; 81 (7): 379-472.
3. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. А.Ш.Ревишвили и др.; Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции (ВНОА). - 3-е изд., доп. и перераб. - М.: МАКС Пресс, 2013. - 596 с.
4. Borne R.T., Varosy P.D., Masoudi F.A. Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches // JAMA Intern Med. 2013; 173(10): 859-865.
5. Proietti R., Labos C., Davis M., et al. A systematic review and meta-analysis of the association between implantable cardioverter-defibrillator shocks and long-term mortality // Can J Cardiol. 2015; 31(3): 270-277.
6. Kleemann T., Strauss M., Kouraki K., et al. Clinical course and prognostic relevance of antitachycardia pacing-terminated ventricular tachyarrhythmias in implantable cardioverter-defibrillator patients // Europace. 2015; 17 (7): 1068-1075.
7. Michael O.S., Mark S.W., Kent V, et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients results from the pacing fast VT reduces shock therapies (PainFREE Rx II) Trial // Circulation 2005; 111: 2898-2905.
8. Guido H.W., Johannes B.R., Borleffs C.J.W., et al. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients // Europace 2011; 13: 389-394.
9. Wijers S.C., Kolk B.Y.M., Tuinenburg A.E., et al. Implementation of guidelines for implantable cardioverter-defibrillator therapy in clinical practice: which patients do benefit? // Neth Heart J. 2013; 21: 274-283.
10. Germano J.J., Reynolds M., Essebag V. et al. Frequency and causes of implantable cardioverter-defibril-lator therapies: is device therapy proarrhythmic? // Am J Cardiol. 2006; 97(8): 1255-1261.
11. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators // N Engl J Med. 1997; 337(22): 1576-1583.
12. Moss A.J., Greenberg H., Case R.B., et al. For the Multicenter Automatic Defibrillator Implantation Trial-II (MA-DIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator // Circulation 2004; 110: 3760-3765.
13. Sedlacek K., Ruwald A.C., Kutyifa V., et al. MADIT-RIT Investigators. The effect of ICD programming on inappropriate and appropriate ICD Therapies in ischemic and nonischemic cardiomyopathy: the MADIT-RIT trial // J Cardiovasc Electrophysiol. 2015 Apr; 26(4): 424-433.
14. Barsheshet A., Wang P.J., Moss A.J. et al. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy) // J Am Coll Cardiol. 2011; 57: 2416-2423.
15. AlJaroudi W.A., Refaat M.M., Habib R.H., et al. Genetic Risk Assessment of Defibrillator Events Investigators. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study) // Am J Cardiol. 2015 Apr; 115(7): 924-931.
16. Heijden A.C. van der, Borleffs C.J., Buiten M.S., et al. The clinical course of patients with implantable cardioverter-defibrillators: Extended experience on clinical outcome, device replacements, and device-related complications // Heart Rhythm. 2015 Jun; 12(6): 1169-1176.
17. Tompkins C.M., Kutyifa V., Arshad A. et al. Sex differences in device therapies for ventricular arrhythmias or death in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) Trial // J Cardiovasc Electrophysiol. 2015; 26(8): 862-871.
18. Koller M.T., Schaer B., Wolbers M., et al. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study // Circulation. 2008; 117(15): 1918-1926.
Review
For citations:
Rychkov A.Yu., Kuznetsov V.A., Dyuryagina E.L., Khorkova N.Yu., Dubrovskaya E.N., Kharats V.E. FREQUENCY OF APPROPRIATE ACTIVATIONS OF IMPLANTED CARDIOVERTERS-DEFIBRILLATORS IN PATIENTS WITH CHRONIC HEART FAILURE. Journal of Arrhythmology. 2015;(81):10-14. (In Russ.)
Views:
157
Email this article 